Rodrigo A. Toledo
rtoledo@vhio.net
Current position
- Group Leader of VHIO’s Biomarkers and Clonal Dynamics
Areas of Research
- Discover and characterize novel predictive biomarkers of response to targeted anticancer therapies.
- Apply multimodal circulating tumor DNA (ctDNA) assays to predict response to immunotherapy and targeted therapies across tumor types.
- Validate RNF43 mutations as biomarkers of clinical benefit in patients with BRAF-mutated CRC treated with anti-BRAF/EGFR combinatory therapies.
- Characterize tumor heterogeneity: examine the temporal heterogeneity of tumors using tumor and liquid biopsy sequencing approaches during treatment response and disease progression, particularly in the context of immunotherapy and targeted therapies.
- Investigate the mechanims of cancer drug resistance to immunotherapy and targeted therapies to identify potential biomarkers of resistance in liquid biopsy that inform more effective treatment strategies.
- Characterize the impact of hypoxia in shaping of cancer genomes and modulating response to cancer therapies.
